Good move, keep watching. $2's are very possible. Another secondary to dilute shareholders. No progress in last five years. Clinical trial pulled with no management comment. Secondary issued with no management comments. Only one remaining "shot" on goal. Rosenberg NCI trial has still not dosed its first patient. IL-12 looks like a bust after being a primary strategy for years. Other Bio companies making great strides; our heralded Sleeping Beauty delivery system on the verge of being completely antiquated as CEO bumbles around letting timeline after timeline slip. Terrible CEO and probably not CMO caliber either (despite being a self proclaimed genius). Lawrence had MDA roots, I bet they do not miss him.
Still hope for share price improvement of course, but buying it as a lottery ticket should be your financial objective. PROF and AUPH are just two of dozens of better investments if you are looking for clinical stage or recently FDA approved companies. Was a bull on this company for years, now just a bag holder on my remaining few shares.
News 
Market Data 
Discover 
